Shareholders back AGT-ChemGenex merger
21 June, 2004 by Iain ScottShareholders of Melbourne-based AGT Biosciences (ASX:AGT) have backed the company's merger with privately-held Californian firm ChemGenex Therapeutics.
News: Researcher's diabetes quest earns reward for excellence
21 June, 2004 by Melissa TrudingerProf Len Harrison, of the Walter and Eliza Hall Institute, has been awarded the David Rumbough award for scientific excellence by the Juvenile Diabetes Research Foundation International for his research towards finding a cure for type 1 diabetes.
Life Therapeutics aims for profit by 2006
18 June, 2004 by Renate KrelleLife Therapeutics -- formerly known as Gradipore (ASX:GDP) -- today capped off its 200-day turnaround plan with a set of profit projections that culminated in a forecast overall profit for the company in 2006 of AUD$4.5 million.
Garvan to team with Shanghai researchers on diabetes project
17 June, 2004 by Graeme O'NeillBy 2025, as many as 157 million overweight Chinese are likely to be suffering from non-insulin dependent (Type 2) diabetes, more than the total for the entire world today.
Lacklustre debut for Regenera
16 June, 2004 by Renate KrellePerth-based opthamology specialist Regenera (ASX:RGA) experienced a lacklustre debut on ASX today. After opening at $0.47 and trading as high as $0.50, it fell below its issue price and at time of writing was trading at $0.49.
Singapore cancer patients implanted with Psivida's Biosilicon
15 June, 2004 by Graeme O'NeillTwo patients in Singapore General Hospital suffering from inoperable liver tumours have become the first cancer patients in the world to be treated with an experimental in situ radiation therapy developed by Perth nano-biotech company Psivida (ASX:PSD).
CSIRO develops new cancer classifier
15 June, 2004 by Melissa TrudingerCSIRO statisticians have developed a new molecular classifier tool which is being tested on clinical bone marrow samples from children with acute lymphoblastic leukaemia (ALL) -- the most common cancer in children under 12 -- as a potential diagnostic tool for identifying the disease and its subtypes.
La Trobe research offers new hope for MS therapy
09 June, 2004 by Graeme O'NeillIt's too early to announce a new dawn, but there's a distinct glow on one of neuroscience's darkest horizons. The enigma of the paralysing central nervous system disorder, multiple sclerosis, may be nearing solution.
Proteome Systems develops EPO test for drug cheat athletes
07 June, 2004 by Graeme O'NeillSydney company Proteome Systems has developed a new test to unmask endurance athletes who try to gain an illegal aerobic edge with the red blood-cell booster erythropoietin (EPO).
News: Sydney researchers uncover cancer's silent culprit
02 June, 2004 by Graeme O'NeillTwo Sydney cancer patients have made medical history as the first individuals to be diagnosed with cancer induced by spontaneous silencing of an otherwise normal tumour-suppressor gene.
Tropical science: Dispersal sends 'em troppo up north
02 June, 2004 by Staff WritersAustralia's tropical research science and innovation efforts are scattered over the continent's top end, from north-western WA to north-eastern Queensland. And addressing the challenges created by that kind of dispersal have become a key priority for the chief scientists of Queensland and Western Australia, along with the Northern Territory's Bob Collins, in the wake of a recent forum in Darwin.
Cancer research: at the frontline
01 June, 2004 by Graeme O'NeillAustralia's biotechnology industry is tiny by comparison with its US and European counterparts, but it offers glimpses of what a future in which most cancers will be curable, or ideally, preventable, writes Graeme O'Neill.
WEHI diabetes researcher honoured
31 May, 2004 by Melissa TrudingerProf Len Harrison, of the Walter and Eliza Hall Institute, has been awarded the David Rumbough award for scientific excellence by the Juvenile Diabetes Research Foundation International for his research towards finding a cure for type 1 diabetes.
Evogenix fine-tunes Absalus antibodies in strategic alliance
28 May, 2004 by Graeme O'NeillIf you need to give your humanised monoclonal antibodies (MAbs) a gecko-like grip on their therapeutic targets, who do you call?
Does Biosilicon deliver? Uni of Pittsburgh to investigate
21 May, 2004 by Melissa TrudingerNanotechnology company pSivida's (ASX: PSD) UK subsidiary pSiMedica has signed a collaborative agreement with the University of Pittsburgh to evaluate the use of BioSilicon as a delivery platform for the university's proprietary DNA vaccine technology.
